SGLT2 Inhibitors – The New HF Therapies on the Block
Published: 25 August 2020
-
Views:
277
-
Likes:
1
Overview
Full programme
-
Views:
277
-
Likes:
1
Overview
In this Educational Symposium from the e-SPACE Heart Failure Global Web-Conference, Subodh Verma, Nikolaus Marx and Shelley Zieroth discuss SGLT2 inhibitors covering their history, a clinical perspective into what we have learned about them and how future trials might affect clinical practice.
These videos were funded by an unrestricted educational grant from Boehringer Ingelheim & Eli Lilly and Company.
Learning objectives
- Raise Awareness of SGLT2 Inhibitors as Cardiovascular Therapies With Cardio–Renal Benefits
- Highlight Appropriate Patients for Initiation of an SGLT2 Inhibitor and Share With Cardiologists the Well-Established Safety Profile and Clinical Considerations for SGLT2 Inhibitor Treatment
- Inform Cardiologists of the Current Evidence and Ongoing Trials for SGLT2 Inhibitors in Patients With HF
Agenda
- 5 mins - Welcome & introduction - Subodh Verma
- 15 mins - A brief history of SGLT2 inhibitors - Subodh Verma
- 15 mins - What have we learned about SGLT2 inhibitors? A clinical perspective - Nikolaus Marx
- 15 mins - How might future trials affect how I might treat my patients? - Shelley Zieroth
- 10 mins - Faculty discussion (pre-recorded) - All Faculty
- Close - Subodh Verma
- Live Q&A and discussion - All Faculty
Series overview
Part 1
Welcome & Introductions
| 1 session | |
| Welcome & Introductions | Watch now |
Part 2
A Brief History of SGLT2 Inhibitors
| 1 session | |
| A Brief History of SGLT2 Inhibitors | Watch now |
Part 3
What Have We Learned About SGLT2 Inhibitors? A Clinical Perspective
Part 4
How Might Future Trials Affect How I Treat My Patients?
Part 5
Panel discussion
| 1 session | |
| Panel discussion | Watch now |
Faculty Biographies
Subodh Verma
Dr Subodh Verma is a cardiac surgeon-scientist at St. Michael’s Hospital, Professor at the University of Toronto and the Canada Research Chair in Atherosclerosis.